CSIR-IICT said Molnupiravir could fully suppress the Covid-19 virus transmission within 24 hours, citing a study published in the journal ‘Nature Microbiology’. CSIR-NIORS also collaborates with SUVEN Pharma for processing process technology, detailed press releases.
In what happened as a boost for the Indian pharmaceutical industry in the middle of the Pandemic Coronavirus (Covid-19) Pandemi, the Scientific and Industrial Research Council – Chemical Institute of Technology (CSIR-IICT), and the Scientific Research Council and the Industry-National Institute of Interdisciplinary Science and Technology ( CSIR-Niist) has signed a MoU with Suva Pharmaceuticals Ltd. (SPL) for the transfer of process technology and making anti-covid molupiravir drugs. The New Testament came a few days after Hyderabad-based CSIR-IICT entered the MOU similar to Lee Pharma on the transfer of process technology and the manufacture of covid-19 2-deoxy-d-glucose drug (2-DG).
Molnupiravir anti-virus drug, is now intended to fight Covid-19, originally developed for influenza treatment but has since been immersed. CSIR-IICT said Molnupiravir could fully suppress the Covid-19 virus transmission within 24 hours, citing a study published in the ‘Nature Microbiology’ research journal. In a fast way to handle the transmission of the SARS-COV-2 virus, anti-covid molnupiravir drugs can be a complete gamechanger in the Indian battle against Coronavirus’s disease, said the Indian Chemical Institute of Technology.
The press release issued by the CSIR-IICT detailed how the synthetic process of knowledge for Molnupiravir is sourced from the CSIR-NIOR and the process of increasing it successfully carried out by CSIR-IICT. It is said that complete technology knows – how to be transferred to SPL and the company, it will in turn producing and launching Molnupiravir anti-virus drugs on the market as an effective drug for patients affected by Coronavirus (Covid-19). CSIR-IICT will also provide a knowledge process for making new anti-covid drugs 2 -dg to treat moderate and severely infected patients to reduce their oxygen dependence, according to the agreement.